Search Results for "Relafen"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Relafen. Results 1 to 6 of 6 total matches.
See also: nabumetone
Nabumetone - A New Nsaid
The Medical Letter on Drugs and Therapeutics • Apr 17, 1992 (Issue 868)
FOR
ONLINE USERS
NABUMETONE — A NEW NSAID
Nabumetone (Relafen − SmithKline Beecham), a new nonsteroidal ...
Nabumetone (Relafen - SmithKline Beecham), a new nonsteroidal anti-inflammatory drug (NSAID), has been approved by the US Food and Drug Administration for treatment of rheumatoid arthritis and osteoarthritis. The drug has been available in the United Kingdom since 1987. The manufacturer claims that nabumetone is as effective as other NSAIDs and causes a relatively low incidence of peptic ulcers.
Dangerous Drugs
The Medical Letter on Drugs and Therapeutics • Dec 06, 2004 (Issue 1197)
), nabumetone
(Relafen, and others) or diclofenac (Voltaren and others),
or acetaminophen (Tylenol, and others ...
At a US Senate hearing prompted by the withdrawal of Vioxx, an FDA officer cited 5 drugs as potentially dangerous. It may be useful to revisit Medical Letter reviews of these drugs.
Oxaprozin for Arthritis
The Medical Letter on Drugs and Therapeutics • Feb 19, 1993 (Issue 890)
or 4 38.74
Meclomen (Parke-Davis) doses 82.24
Nabumetone− Relafen (SmithKline Beecham) 1000 once/day ...
Oxaprozin (Daypro -Searle), a propionic acid-derivative nonsteroidal anti-inflammatory drug (NSAID), has been approved by the US Food and Drug Administration for once-daily treatment of rheumatoid arthritis and osteoarthritis. Some of the NSAIDs previously marketed in the USA are listed in the table on page 16. Ibuprofen, naproxen, fenoprofen, ketoprofen, and flurbiprofen are also propionic acid derivatives. Piroxicam and nabumetone (Medical Letter, 34:38, 1992) are also approved for once-daily use, and indomethacin is available in an extended-release formulation that can be taken once...
Meloxicam (Mobic) for Osteoarthritis
The Medical Letter on Drugs and Therapeutics • May 29, 2000 (Issue 1079)
59.40
Nabumetone − Relafen (SmithKline Beecham) 1000 mg once/day to 2000 mg/day 76.23
Naproxen ...
Meloxicam, a nonsteroidal anti-inflammatory drug (NSAID) with some cyclooxygenase-2 (COX-2) selectivity in vitro, has been approved by the FDA for treatment of osteoarthritis.
Drugs that Cause Photosensitivity
The Medical Letter on Drugs and Therapeutics • Apr 14, 1995 (Issue 946)
, and others)
Nabumetone (Relafen)
Naproxen (Naprosyn, and others)
Phenylbutazone (Butazolidin, and others ...
As the weather becomes warmer, physicians may see more photosensitivity reactions due to systemic or topical drugs, perfumes, cosmetics or sunscreens. Even brief exposure to sunlight in warm or cold weather can cause intense cutaneous reactions in patients with drug-induced photosensitivity, and some patients may continue to be sensitive to sunlight long after stopping use of the offending agent.
COX-2 Alternatives and GI Protection
The Medical Letter on Drugs and Therapeutics • Nov 08, 2004 (Issue 1195)
) and nabumetone (Relafen, and others).
Theoretically, these drugs might cause less GI toxicity
than nonselective ...
With the removal of Vioxx from the market and concerns about cardiovascular toxicity with other selective COX-2 inhibitors, patients are looking for safe alternatives, and manufacturers of other drugs are looking for additional market share. The COX-2 inhibitors first became popular because they have less upper GI toxicity than older less selective NSAIDs, at least in the short term, in patients not taking aspirin.